According to filings with the U.S. Securities and Exchange Commission, Xenon Ophthalmics is raising $2,365,500.00 in new funding. Sources indicate that as part of senior management Chief Executive Officer, Zeshan Kahn played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About Xenon Ophthalmics
Xenon Ophthalmics Inc. is a medical device and technology company committed to bringing the next generation of medical-grade diagnostic screening equipment to the global eyecare marketplace for use by Ophthalmologists, Optometrists, eyecare clinics, and primary care providers. Our products offer multi-function diagnostic screening using a highly evolved eyecare device that employs the latest technology in Eye-Tracking Software (ETS), Artificial Intelligence (AI), and Virtual Reality (VR) Platforms with retinal display to deliver accurate and cost-effective solutions for eyecare diagnosis. Our XO Exam VFT (Visual Field) and ABT (Aberrometry) medical-grade headset units are cutting-edge wearable devices that can perform multiple eye examinations and screen for the following eye diseases, including but not limited to Glaucoma, Diabetic Retinopathy, and Age-related Macular Degeneration (AMD). Our XO Exam headset units offer a new paradigm in ophthalmic examination and diagnosis: The exam can be performed by a doctor remotely or in the same room as the patient, a significant advancement in global telemedicine. The product enhances the quality of access, care, and comfort for patients. Doctors can expand their practice and see more patients without the addition of expensive equipment and dedicated square footage.

To learn more about Xenon Ophthalmics, visit http://www.xophthalmics.com/

Contact:
Zeshan Kahn, Chief Executive Officer
973-619-4071

SOURCE: http://www.intelligence360.io
Copyright (c) 2023 SI360 Inc. All rights reserved.